Zealand Pharma

Latest Headlines

Latest Headlines

Zealand inks a $402M cardio-metabolic peptide program with Boehringer

Early this year Zealand Pharma and Boehringer Ingelheim agreed to start over on their three-year-old collaboration to develop a GLP-1 diabetes drug after they decided to part ways on a lead program. Now the Danish biotech will ramp up a second preclinical peptide program with the German pharma company aimed at cardio-metabolic diseases.

Boehringer, Zealand hit reset on GLP-1 diabetes program

After more than two years of work on a GLP-1-targeting diabetes drug, partners Boehringer Ingelheim and Zealand Pharma are planning to start over, hitting the brakes on their program and looking to move on with a to-be-determined new compound.

Boehringer, Zealand team on €376M diabetes and obesity pact

Boehringer Ingelheim has struck a deal with Zealand Pharma that gives the German drugmaker access to early-stage Type 2 diabetes and obesity candidates. It's a pact that could support Boehringer's

Sanofi GLP-1 diabetes drug edges Byetta in Phase III study

Building up its war chest of positive data for the Type 2 diabetes drug lixisenatide, Sanofi-Aventis has hit another primary goal in a late stage study: Non-inferiority to Byetta (exenatide) for

Uphill climb gets even steeper for biotech IPOs

Wall Street may have had its arms open wide for GM's new market debut, but drug developers are finding the same chilly disdain for red ink that has greeted almost every offering this year. Zogenix

Zealand Pharma tests chilly IPO waters

A Danish newspaper is reporting that Zealand Pharma--the biotech responsible for initially developing the late-stage diabetes drug lixisenatide and then licensing it to Sanofi--is poised to launch an

Report: Deal-hungry Sanofi eyes stake in Zealand Pharma

Sanofi-Aventis' strategy to do more partnering with the world's most promising biotech companies may spur the pharma giant to take a $143 million stake in Denmark's Zealand Pharma. The two companies

Zealand Pharma inks $177M pact for early-stage compound

Denmark's Zealand Pharma has licensed out the worldwide rights--outside of the Nordic countries--to an early-stage compound targeting chemotherapy-induced diarrhea. Helsinn gained the marketing